Precision for Medicine acquires Applied Immunology

3 May 2016

US biomarker research company Precision for Medicine, part of the Precision Medicine Group, has acquired specialty research laboratory Applied Immunology, it has been announced.

Applied Immunology is an expert in the creation and delivery of custom cell-based and immunoassay solutions, with a client base including some of the most pioneering new venture-backed startups, as well as several major global pharma companies.

The deal with strengthen and expand Precision’s specialty laboratory services in cell-based and immunoassays and creates state-of-the-art lab access for Precision’s west coast biotechnology clients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK